Home > Result Summaries: Compounds > Human Papillomavirus Types 16 and 18 Vaccine > Result Summary for 580299/004

Result Summary for 580299/004

Result Summary

Protocol ID:	580299/004
Clinical Study ID:	580299/004
Official Title:	Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine against Human Papillomavirus Types 16 and 18, when Formulated with Aluminum Hydroxide, AS04, or without Adjuvant, in Healthy Adult Female Volunteers
Phase:	Phase 2
Study Indications or Diseases:	Papillomavirus Vaccines
Generic Name:	Human Papillomavirus Types 16 and 18 Vaccine
Trade/Product Name:	Cervarix
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Verstraeten T et al. (2008) Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 26(51):6630–6638. Descamps D et al. (2009) Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials. Hum Vaccin. 5(5):51-59. Giannini S et al. (2006) Enhanced humoral and memory B cellular immunity using HPV 16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 24(33-34):5937-5949.